NCT03563378

Brief Summary

Lactated Ringer(LR) has been extensively used to maintain and replace intravascular volume in a variety of anesthetic procedures. However, the utility of LR in pediatric with hepatic failure undergoing liver transplantation is unclear, because addition of exogenous lactate may increase lactate concentration. In addition,large amounts of normal saline(NS) which does not contain lactate can induce a hyperchloremic metabolic acidosis and have been asociated with adverse effects on kidney injury, coagulation, and death. Accordingly, the investigators performed a double-blinded randomized trial comparing the effects of intraoperative NS or LR on outcomes in pediatric receiving Liver transplantation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 21, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 20, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

July 28, 2018

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 27, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 27, 2020

Completed
Last Updated

June 20, 2018

Status Verified

June 1, 2018

Enrollment Period

1.8 years

First QC Date

May 21, 2018

Last Update Submit

June 19, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in lactate level of the lactated ringer group compared to the normal saline group

    Baseline serum lactate will be measured after randomization and again after surgery, then every 24 hours for 72 hours

    up to 3 days after surgery

Secondary Outcomes (3)

  • Length of mechanical ventilation

    up to 30 days after surgery

  • ICU stay

    up to 30 days after surgery

  • 30 day mortality

    up to 30 days after surgery

Study Arms (2)

Lactated ringers solution

EXPERIMENTAL

Participants in this group will receive Lactated Ringer's solution during the intraoperative period.

Drug: Lactated Ringer

Normal saline solution

EXPERIMENTAL

Participants in this group will receive Normal saline solution during the intraoperative period.

Drug: Normal saline

Interventions

Patients will be administered Lactated Ringer's solution for intraoperative fluid management.

Lactated ringers solution

Patients will be administered normal saline for intraoperative fluid management.

Normal saline solution

Eligibility Criteria

Age3 Months - 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Pediatric patients between the age of 3 month and 6 years
  • Scheduled for living donor liver transplantation

You may not qualify if:

  • Re-transplantation
  • Combined liver and kidney transplantation
  • Congenital heart disease
  • Refused to participate the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

RECRUITING

MeSH Terms

Interventions

Ringer's LactateSaline Solution

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • qi lu, Dr.

    Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    PRINCIPAL INVESTIGATOR

Central Study Contacts

diansan su, Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2018

First Posted

June 20, 2018

Study Start

July 28, 2018

Primary Completion

May 27, 2020

Study Completion

May 27, 2020

Last Updated

June 20, 2018

Record last verified: 2018-06

Locations